CERo Therapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CERo Therapeutics Holdings generated cash of -$1,523, which is more than the previous year. Cash used in financing activities reached the amount of -$32,576 last year. Net change in cash is therefore -$42,044.
Cash Flow
| 2022 | -1.09M | 180.83M | -138.70M |
|---|---|---|---|
| 2023 | -1.52K | -7.94K | -32.57K |
CERO Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 42.14K | 1.09M |
Operating activities | ||
Net income | -2.53K | -667.73K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 1.07M |
Stock-based compensation expense | 0 | 381.07K |
| Deferred income tax benefit | 0 | 381.07K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 0 | -68.73K |
Cash generated by operating activities | -1.52K | -1.09M |
Investing activities | ||
Purchases Of Investments | -14.33M | -325K |
Investments In Property Plant And Equipment | 0 | -694.23K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -7.94K | 180.83M |
Financing activities | ||
Common Stock Issued | 0 | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | -33.48K | -139.35M |
Repayments of term debt | 905K | 650K |
Cash used in financing activities | -32.57K | -138.70M |
Net Change In Cash | -42.04K | 41.04M |
Cash at end of period | 96 | 42.14M |